{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:35:59Z","timestamp":1768516559757,"version":"3.49.0"},"reference-count":12,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T00:00:00Z","timestamp":1510790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Exper Ophthalmology"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Importance<\/jats:title><jats:p>To assess the impact of injection frequency on visual outcomes in patients with neovascular age\u2010related macular degeneration (nAMD) treated with intravitreal aflibercept.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>The UK licence for treatment of nAMD with aflibercept is based on the VIEW protocol. We tested the hypothesis that patients receiving fewer than the eight recommended injections in the first year would experience worse visual outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective, single\u2010centre observational study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>There were 42 eyes from 42 patients included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Fight Retinal Blindness! software was used to record real\u2010world outcomes of all treatment\u2010na\u00efve eyes receiving aflibercept for at least 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcome Measures<\/jats:title><jats:p>Visual acuity (VA) at 1 year in eyes which received the recommended eight injections <jats:italic>versus<\/jats:italic> those receiving seven or fewer injections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 21 eyes (50%) that received the recommended eight aflibercept injections in the first year of treatment, whilst 14 eyes received seven injections, five received six injections and two received only five injections, with median VA change +7.0, +5.0, \u22124.0 and \u22126.5 LogMAR letters, respectively. Those eyes receiving seven or fewer injections had worse baseline vision. The main reasons for patients being undertreated were insufficient clinic capacity and non\u2010attendance due to illness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Patients in the real\u2010world receiving aflibercept for nAMD at fixed intervals as per UK licence could achieve similar visual improvement at 1 year compared with phase III clinical trials. Undertreated patients had worse visual outcomes. Measures need to be introduced to increase clinic capacity and closely follow non\u2010attenders to improve future outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ceo.13085","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T08:22:49Z","timestamp":1508228569000},"page":"407-411","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Real\u2010world visual outcomes in patients with neovascular age\u2010related macular degeneration receiving aflibercept at fixed intervals as per UK licence"],"prefix":"10.1111","volume":"46","author":[{"given":"Mehmet","family":"Ozturk","sequence":"first","affiliation":[{"name":"Department of Ophthalmology Royal Free London NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin L","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Royal Free London NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9070-9803","authenticated-orcid":false,"given":"Vuong","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Macular Research Group Save Sight Institute, University of Sydney  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[{"name":"Macular Research Group Save Sight Institute, University of Sydney  Sydney New South Wales Australia"},{"name":"Department of Ophthalmology University Hospital Zurich, University of Zurich  Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark C","family":"Gillies","sequence":"additional","affiliation":[{"name":"Macular Research Group Save Sight Institute, University of Sydney  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemal","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Royal Free London NHS Foundation Trust  London UK"},{"name":"Macular Research Group Save Sight Institute, University of Sydney  Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,11,16]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.195370"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.10.052"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.1"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318296b271"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.05.010"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.039"},{"key":"e_1_2_5_9_1","first-page":"1","article-title":"Two year outcomes of \"treat and extend\" intravitreal therapy using Aflibercept preferentially for Neovascular age\u2010related macular degeneration","author":"Barthelmes D","year":"2017","journal-title":"Retina"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-306229"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.143"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001142"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-303233"}],"container-title":["Clinical &amp; Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fceo.13085","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ceo.13085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:02:44Z","timestamp":1695510164000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ceo.13085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,16]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/ceo.13085"],"URL":"https:\/\/doi.org\/10.1111\/ceo.13085","archive":["Portico"],"relation":{},"ISSN":["1442-6404","1442-9071"],"issn-type":[{"value":"1442-6404","type":"print"},{"value":"1442-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,16]]},"assertion":[{"value":"2017-08-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}